



PROGRAM AT A GLANCE August 26 (Thu.)

Time	CHANNEL A	CHANNEL B
09:00-09:30	ICBMT 2021 VIRTUAL OPENING CEREMONY	
09:30-10:30	<p>PLENARY SESSION 1 Genomics in Transplantation Chair: Sung-Soo Yoon</p> <p>NGS-based MRD Monitoring Pre- and Post-Allogeneic HSCT for AML Michael Heuser, Germany</p> <p>Conditioning Intensity of Allogeneic Transplantation for AML with MRD Christopher S. Hourigan, USA</p>	
10:30-10:40	Break	
10:40-11:10	<p>PLENARY SESSION 2 State of the Art in CAR-T Cell Therapy Chair: Jong Ho Won</p> <p>Next Generation CAR-T Cell Therapy in Multiple Myeloma Sham Mailankody, USA</p>	
11:10-11:20	Break	
11:20-12:20	<p>PLENARY SESSION 3 Data Science for Research in Hematopoietic Cell Transplantation Chair: Young Tak Lim</p> <p>Development and Application of Machine Learning in Hematopoietic Stem Cell Transplantation Yasuyuki Arai, Japan</p> <p>Current Statistical Issues in Hematopoietic Cell Transplantation Haesook T. Kim, USA</p>	
12:20-12:40	Break	
12:40-13:20	<p>INDUSTRY SYMPOSIUM 1</p> <p> Chair: Je-Hwan Lee</p> <p>Mastering the Evolution in Therapy-Related Acute Myeloid Leukemia & Acute Myeloid Leukemia with Myelodysplasia-Related Change Hawk Kim, Korea</p>	<p>INDUSTRY SYMPOSIUM 2</p> <p> Chair: Chang-Ki Min</p> <p>Optimizing Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Thomas Martin, USA</p>
13:20-13:30	Break	



PROGRAM AT A GLANCE August 26 (Thu.)

Time	CHANNEL A	CHANNEL B
13:30-14:30	ORAL SESSION 1	ORAL SESSION 2
14:30-14:40	Break	
14:40-16:10	SCIENTIFIC SESSION 1 The Road to Genomics Enlightening the Acute Leukemia with or without BMT Chairs: Hee-Je Kim, Joon Seong Park	JOINT SYMPOSIUM 1 JSTCT-KSBMT: Complication Management after Allo-HSCT Chairs: Takanori Teshima, Hoon Kook Infectious Complication: CMV Infection in Korea Yae-Jean Kim, Korea Infectious Complication: HHV-6 Infection in Japan Masao Ogata, Japan Gut GVHD-microbiome Dong-Mi Shin, Korea Intestinal Dysbiosis and GVHD; Preclinical and Clinical Findings Daigo Hasimoto, Japan
	High Throughput Single Cell Analysis in AML Koichi Takahashi, USA Therapeutic Implications of Genomic Profiling in Acute Myeloid Leukemia Omar Abdel-Wahab, USA Clonal Hematopies of Indeterminate Potential in Transplantation Kyoung Ha Kim, Korea	
16:10-16:20	Break	
16:20-16:30	Break	
16:30-18:00	SCIENTIFIC SESSION 2 Maintenance Treatment Strategies after Allogeneic HSCT in the Novel Agent Era Chairs: Je-Hwan Lee, Young Rok Do	SCIENTIFIC SESSION 3 Pediatric ALL Chairs: Hong Hoe Koo, Hyoung Jin Kang Current Ultimate Choice for Conditioning Regimens Christina Peters, Austria HSCT Incorporation with Non-Traditional Agents: Clofarabine, Treosulfan Franca Fagioli, Italy Treatment after Failure of CD-19 Directed Therapy Nirali N. Shah, USA
	FLT3 Inhibitor Maintenance Therapy after Allogeneic HSCT in FLT3 Mutated AML Richard T. Maziarz, USA Maintenance Therapy (Hypomethylating Agents, Bcl2-Inhibitor, Check Point Inhibitors, and Other Novel Drugs) after Allogeneic HSCT in AML and MDS Tapan Kadia, USA Treatment Strategies after Allogeneic HSCT in Relapsed ALL Ik-Chan Song, Korea	
18:00-18:10	Break	
18:10- 18:40	POSTER PRESENTATION 1	POSTER PRESENTATION 2



PROGRAM AT A GLANCE August 26 (Thu.)

Time	CHANNEL C	CHANNEL D
09:00-09:30		
09:30-10:30		
10:30-10:40	Break	
10:40-11:10		
11:10-11:20	Break	
11:20-12:20		
12:20-12:40	Break	
12:40-13:20	<p style="text-align: center;">INDUSTRY SYMPOSIUM 3</p> <p style="text-align: center;"> Bristol Myers Squibb™</p> <p style="text-align: center;">Chair: Dong-Wook Kim</p> <p style="text-align: center;">Elevating the CML Treatment Goals by Personalizing Treatment with Dasatinib Jeff Lipton, Canada</p>	<p style="text-align: center;">INDUSTRY SYMPOSIUM 4</p> <p style="text-align: center;"> NOVARTIS</p> <p style="text-align: center;">Chair: Jin Seok Kim</p> <p style="text-align: center;">KYMRIAH: Rewriting Cancer Survival in DLBCL Michael Dickinson, Australia</p>
13:20-13:30	Break	
13:30-14:30	ORAL SESSION 3	ORAL SESSION 4
14:30-14:40	Break	
14:40-16:10	<p style="text-align: center;">EDUCATION SESSION 1</p> <p style="text-align: center;">Critical Post-transplantation Complications</p> <p style="text-align: center;">Chairs: Seong Kyu Park, Byung Sik Cho</p> <p>VOD/SOS: Prophylactic, Preemptive and Curative Treatment Paul Richardson, USA</p> <p>Transplantation-associated TMA: Pathophysiology, Risk Factors and Management Christopher Dandoy, USA</p> <p>Management of Hemorrhagic Cystitis Ja Min Byun, Korea</p>	<p style="text-align: center;">NURSING SESSION 1</p> <p style="text-align: center;">[Kor]</p> <p style="text-align: center;">Current Status of Blood and Marrow Transplantation and the Role of Nurses</p> <p style="text-align: center;">Chair: Ji-Na Bok</p> <p>Current Status of Blood and Marrow Transplantation in Korea Hye youn Lee, Korea</p> <p>The Role of Coordinator Nurses in Field of Hematopoietic Stem Cell Transplantation Minjin Choi, Korea</p>



PROGRAM AT A GLANCE August 26 (Thu.)

Time	CHANNEL C	CHANNEL D
16:10-16:20	Break	Break
16:20-16:30	<p style="text-align: center;">JOINT SYMPOSIUM 2</p> <p style="text-align: center;">EBMT-KSBMT: Paradigm Shift in Hodgkin Lymphoma; Bridging Therapy to Allo-HSCT (Novel Agent Before and after Allo-HSCT) and PTCy in Haplo-HSCT</p> <p style="text-align: center;">Chairs: Nicolaus Kroeger, Hoon Kook</p> <p style="text-align: center;">Bridging Therapy To Allo-HSCT (Novel Agent before and after Allo-HSCT) Ali Bazarbachi, Lebanon</p> <p style="text-align: center;">Novel Agents for Relapsed or Refractory Hodgkin Lymphoma in Korea Won Seog Kim, Korea</p> <p style="text-align: center;">PTCy in Haplo-HSCT in HL Anna Sureda, Spain</p> <p style="text-align: center;">Allo-HSCT in Hodgkin Lymphoma in Korea Seok-Goo Cho, Korea</p>	Break
16:30-18:00		<p style="text-align: center;">CASE DISCUSSION 1&2</p> <p style="text-align: center;">[Kor]</p> <p style="text-align: center;">1. Adult [16:30-17:10] Moderator: Deok Hwan Yang Primary CNS Lymphoma Yoon Seok Choi, Korea</p> <p style="text-align: center;">2. Ex Vivo T-cell Depletion vs. PTCy for Upfront Haploidentical Transplantation in Pediatric Very Severe Aplastic Anemia [17:20-18:00] Moderator: Keon Hee Yoo Ex Vivo TCD Side Sung Han Kang, Korea PTCy Side Kyung Taek Hong, Korea</p>
18:00-18:10	Break	
18:10-18:40	POSTER PRESENTATION 3	POSTER PRESENTATION 4



PROGRAM AT A GLANCE August 27 (Fri.)

Time	CHANNEL A	CHANNEL B
09:00-10:30	SCIENTIFIC SESSION 4 High Risk Multiple Myeloma Chairs: Ki Hyun Kim, Jin Seok Kim Mass Spectrometry for Detection of Minimal Residual Disease in Multiple Myeloma Noemi Puig, Spain The Role of Tandem Autologous Transplantation for High Risk Multiple Myeloma Hyeon-Seok Eom, Korea CART Therapy for Relapsed/Refractory Multiple Myeloma Nina Shah, USA	JOINT SYMPOSIUM 3 ASTCT-KSBMT: Minimal Residual Disease in Allogeneic HCT or Cellular Therapy Chairs: John DiPersio, Hoon Kook The Role of Flow-, PCR- and NGS-based MRD in Guiding HCT and CART-cell Therapy for Acute Lymphoblastic Leukemia Michael Pulsipher, USA NGS-based MRD Before and After Allogeneic HCT in Myeloid Neoplasms Myungshin Kim, Korea Molecular Measurable Residual Disease for AML Patients Who Undergoing HSCT Byung Sik Cho, Korea
10:30-10:40	Break	Break
10:40-10:50	Break	Break
10:50-12:20	SCIENTIFIC SESSION 6 New and Emerging Therapeutics for Acute and Chronic GVHD Chairs: Kyoo-Hyung Lee, Deog-Yeon Jo Ibrutinib and Other B Cell Directed Therapy in Chronic GVHD Corey Cuttler, USA Ruxolitinib for GVHD Management Robert Zeiser, Germany Intestinal Goblet Cell and IL-25 in Intestinal GVHD Takanori Teshima, Japan	EDUCATION SESSION 3 HSCT in Rare Hematologic Malignancies Chairs: Sung-Hyun Kim, Ki-Seong Eom The Role of Stem Cell Transplantation for WM Masatochi Sakurai, Japan HSCT in Patients with Blastic Plasmacytic Dendritic Cell Neoplasm Ji Hyun Lee, Korea Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis. For Whom, When and How? Chul Won Jung, Korea
12:20-12:30	Break	
12:30-13:10	INDUSTRY SYMPOSIUM 6  MSD <small>INVENTING FOR LIFE</small> Chair: Hyeon-Seok Eom CMV Prophylaxis for Allogeneic HSCT Patients Youngil Koh, Korea	INDUSTRY SYMPOSIUM 7  GYOWA KIRIN Chair: Sung-Soo Yoon Updated Treatment Strategy of Immune Thrombocytopenia with TPO Receptor Agonist Jun Ho Jang, Korea
13:10-13:20	Break	
13:20-14:20	ORAL SESSION 5	ORAL SESSION 6
14:20-14:30	Break	



PROGRAM AT A GLANCE August 27 (Fri.)

Time	CHANNEL A	CHANNEL B
14:30-15:10	PRESIDENTIAL SYMPOSIUM Chair: Hoon Kook	
	Making Sense of CAR-T Cell Therapy for Lymphoma David G Maloney	
15:10-15:20	Break	
15:20-16:50	SCIENTIFIC SESSION 7 Cell Therapy I (non CAR-T) Chairs: Seok-Goo Cho, Ho-Jin Shin	SCIENTIFIC SESSION 8 Alternative Donor Transplant for SAA Chairs: Jong Wook Lee, Hawk Kim
	<p>CAR-NK Cells: A Promising Cellular Immunotherapy for Hematologic Malignancies Jianhua Yu, USA</p> <p>Adoptive T-Cell Immunotherapy- Experiences in Preclinical and Clinical Studies Tai-Gyu Kim, Korea</p> <p>Novel Immunotherapeutic Approaches with Antibody Drugs Hermann Einsele, Germany</p>	<p>Haploidentical Transplantation with PTCy for SAA Régis Peffault de Latour, France</p> <p>Haploidentical Transplantation with ATG for SAA Sung-Eun Lee, Korea</p> <p>Immunosuppressive Therapy Versus Haploidentical Transplantation in Adults with SAA Xiao Jun Huang, China</p>
16:50-17:00	Break	
17:00-18:00	ORAL SESSION 9	ORAL SESSION 10
18:00-18:10	Break	
18:10-18:40	POSTER PRESENTATION 5	POSTER PRESENTATION 6



PROGRAM AT A GLANCE August 27 (Fri.)

Time	CHANNEL C	CHANNEL D
09:00-10:30	<p>SCIENTIFIC SESSION 5 [09:00-11:00]</p> <p>HSCT in Pediatric Non-Malignant Disease Chair: Kyung-Ha Ryu, Nack-Gyun Chung</p> <p>Treosulfan Based Conditioning for Nonmalignant Diseases Ho Joon Im, Korea</p> <p>HSCT and Gene Therapy for Primary Immunodeficiency Andrew Gennery, UK</p> <p>Optimizing the Conditioning Regimen of HSCT for Acquired Bone Marrow Failure in Children Nao Yoshida, Japan</p> <p>Bridge to Transplantation for Refractory HLH Michael B Jordan, USA</p>	<p>EDUCATION SESSION 2 [Kor]</p> <p>Long Term Management of Allogeneic Stem Cell Transplant Recipients Chairs: Jae-Sook Ahn, Jae Wook Lee</p> <p>Nutritional Management in Patients Treated with Stem Cell Transplantation Ka-Won Kang, Korea</p> <p>Management of Long-Term Endocrine Complications after Hematopoietic Stem Cell Transplantation Jin-Ho Choi, Korea</p> <p>Fertility Preservation and Reproductive Health in Allogeneic Hematopoietic Stem Cell Transplantation Seungmin Hahn, Korea</p>
10:30-10:40		Break
10:40-10:50		Break
10:50-12:20	<p>Break</p> <p>INDUSTRY SYMPOSIUM 5 [11:40-12:20]</p> <p> Chair: Hee-Je Kim</p> <p>Optimal Treatment Strategy for FLT3 Mutated AML Andrew Wei, Australia</p>	<p>JOINT SYMPOSIUM 4</p> <p>Advances in Biology and Clinical Application of Cellular Therapy: CAR-T Therapy in Solid Malignancy Chairs: John Rasko, Je-Jung Lee</p> <p>CAR-T Cell Therapy on Pancreatic Cancer John Rasko, Australia</p> <p>CAR-T Cell Therapy Beyond Blood Cancer Treatment Baekseung Lee, Korea</p> <p>Development of IL13Ra2-Targeted Chimeric Antigen Receptor T Cells against Malignant Glioma Song-Jae Lee, Korea</p>
12:20-12:30	Break	
12:30-13:10	<p>INDUSTRY SYMPOSIUM 8</p> <p> Chair: Je-Jung Lee</p> <p>CART-Cell Therapies for Multiple Myeloma: Where are We Now and What are the Key Issues? Thomas G. Martin, USA</p>	<p>INDUSTRY SYMPOSIUM 9</p> <p> Chair: Hyoung Jin Kang</p> <p>Current Strategy for MRD Positive and Relapse ALL Itaru Kato, Japan</p>
13:10-13:20	Break	



PROGRAM AT A GLANCE August 27 (Fri.)

Time	CHANNEL C	CHANNEL D
13:20-14:20	ORAL SESSION 7	ORAL SESSION 8
14:20-14:30	Break	
14:30-15:10		
15:10-15:20	Break	
15:20-16:50	EDUCATION SESSION 4 Advances in the Laboratory Medicine Chairs: Myungshin Kim, Young-Uk Cho	EDUCATION SESSION 5 [Kor] Statistics in HSCT Chairs: Joon Ho Moon
	Germline Predisposition: an Emerging Issue in Donor Selection for HSC Lucy A Godley, USA NGS-based HLA Typing Yun Ji Hong, Korea Chimerism Monitoring Using NGS Assay Hyun-Ji Lee, Korea	Statistical Methods in HSCT Hwa Jung Kim, Korea Designing Clinical Studies in the HSCT Setting Seokyung Hahn, Korea
16:50-17:00	Break	
17:00-18:00	ORAL SESSION 11	ORAL SESSION 12
18:00-18:10	Break	
18:10-18:40	POSTER PRESENTATION 7	POSTER PRESENTATION 8



PROGRAM AT A GLANCE August 28 (Sat.)

Time	CHANNEL A	CHANNEL B
07:30-09:00	KSBMT Business Meeting	
09:00-10:30	SCIENTIFIC SESSION 9 Cell Therapy II (CAR-T) Chairs: Je-Jung Lee, Duck Cho	SCIENTIFIC SESSION 10 The Role of Stem Cell Transplantation in Lymphoma in the Era of Novel and Cell Therapy Chairs: Seok Jin Kim, Dok Hyun Yoon
	'Off the shelf' CAR-T Cells for Relapsed Refractory Lymphoma and MM Sattva S Neelapu, USA Integrating CAR-T Cell Therapy and Transplantation Peihua Lu, China Real World Experience of CAR-T Cells in Korea Won Seog Kim, Korea	Autologous Stem Cell Transplantation for Aggressive B-cell Lymphomas in the Frontline Setting: Current Controversies and Advances Narendranath Epperla, USA High Dose Therapy and Autologous Stem Cell Transplantation in Patients with Indolent Lymphoma Julie Vose, USA The Role of Allogeneic Stem Cell Transplantation for Relapsed and Refractory Lymphoma in the Era of CAR-T Cell Therapy Youngwoo Jeon, Korea
10:30-10:40	Break	
10:40-12:10	SCIENTIFIC SESSION 12 Donor Lymphocyte Infusion after HSCT Chair: Chuhi Joo Lyu, Hyeoung-Joon Kim	SCIENTIFIC SESSION 13 Advancing Science Together for a Better Future of HSCT Chairs: Hoon Kook, Jae-Yong Kwak
	Prophylactic/preemptive DLI: Real World Experience Xiao Jun Huang, China Therapeutic DLI in Relapsed/Refractory Hematologic Malignancy Bhagirathbhai Dholaria, USA Post-transplantation Cyclophosphamide based Haploidentical Transplantation and Donor Lymphocyte Infusion Hyoung Jin Kang, Korea	Error-corrected Next Generation Sequencing to Detect MRD in AML Nikhil Patkar, India Haploidentical CD19 CAR-T Cell for Treatment of Relapsed Refractory ALL Suradej Hongeng, Thailand Hematopoietic Stem Cell Transplantation Have Relation with Clinical Phenotype of Fanconi Anemia Patients: Iranian Experience Amir Ali Hamidieh, Iran
12:10-12:20	Break	
12:20-12:30	CLOSING CEREMONY	
12:30-13:00	ICBMT General Assembly	



PROGRAM AT A GLANCE August 28 (Sat.)

Time	CHANNEL C	CHANNEL D
07:30-09:00		
09:00-10:30	<p>SCIENTIFIC SESSION 11 Best Donor for Allogeneic HSCT: Beyond Matched Sibling Donor Chairs: Ho Joon Im, Chul Won Choi</p> <p>Comparison of Allogeneic Stem Cell Transplantation from Matched Unrelated Donor (URD) and Haploidentical Family Donor (HFD) in Adults with Hematological Malignancies Focusing on Acute Leukemia Arnon Nagler, France</p> <p>Cord Blood Versus Haploidentical Stem Cell Transplantation for Hematological Malignancies Jae-Ho Yoon, Korea</p> <p>Unrelated Donor vs Haploidentical $\alpha\beta$ T-cell- and B-cell-depleted HSCT in Children with Acute Leukemia Alice Bertaina, USA</p>	<p>NURSING SESSION 2 [Kor] New Therapy of Hematology and Stem Cell Transplantation Chair: Mee Ok Choi</p> <p>Immunotherapy and Targeted Therapy in Hematologic Malignancy Ja Min Byun, Korea</p> <p>Introduction of CAR-T Therapy Sang Eun Yoon, Korea</p>
10:30-10:40	Break	
10:40-12:10	<p>JOINT SYMPOSIUM 5 TSBMT-KSBMT: Second Malignancies after Allo-HSCT & Auto-HSCT Chairs: Hasan Atilla Ozkan, Young Tak Lim</p> <p>Second Malignancies after Allo-HSCT & Auto-HSCT in Turkey Huseyin Saffet Bekoz, Turkey</p> <p>Secondary Malignancy Following Allogeneic Stem Cell Transplantation in Adult Patients Seung-Hwan Shin, Korea</p>	<p>STUDENT/RESIDENT LECTURE [Kor] Chairs: Won Sik Lee, Young-Ho Lee</p> <p>Current Progress in Cellular Immunotherapy for Hematologic Malignancies Sung-Hoon Jung, Korea</p> <p>Understanding the Role of Genetics in Hematologic Malignancies Saeam Shin, Korea</p> <p>Long-term Management in Pediatric Patients after HSCT Eu Jeen Yang, Korea</p>
12:10-12:20	Break	
12:20-12:30		
12:30-13:00		